Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Overall MarketRank^™

1.63 out of 5 stars

Medical Sector

374th out of 2,041 stocks

Pharmaceutical Preparations Industry

171st out of 769 stocks

4.2 Analyst's Opinion

Consensus Rating
Ionis Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 6 buy ratings, 8 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $57.59, Ionis Pharmaceuticals has a forecasted upside of 56.0% from its current price of $36.91.
Amount of Analyst Coverage
Ionis Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.3 Community Rank

Outperform Votes
Ionis Pharmaceuticals has received 645 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Ionis Pharmaceuticals has received 781 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Ionis Pharmaceuticals has received 54.77% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote “Outperform” if you believe IONS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IONS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Ionis Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Ionis Pharmaceuticals does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ionis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,810.00 in company stock.
Percentage Held by Insiders
Only 2.40% of the stock of Ionis Pharmaceuticals is held by insiders.
Percentage Held by Institutions
84.14% of the stock of Ionis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Ionis Pharmaceuticals are expected to decrease in the coming year, from ($0.53) to ($0.63) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ionis Pharmaceuticals is 76.90, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.08.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ionis Pharmaceuticals is 76.90, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 43.73.
Price to Book Value per Share Ratio
Ionis Pharmaceuticals has a P/B Ratio of 3.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions

Is Ionis Pharmaceuticals a buy right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 1 sell rating, 8 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Ionis Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares.
View analyst ratings for Ionis Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Ionis Pharmaceuticals?

Wall Street analysts have given Ionis Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ionis Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Ionis Pharmaceuticals' next earnings date?

Ionis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Ionis Pharmaceuticals.

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) posted its quarterly earnings data on Wednesday, May, 5th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.16. The firm had revenue of $112 million for the quarter, compared to analysts' expectations of $134.93 million. Ionis Pharmaceuticals had a trailing twelve-month return on equity of 6.57% and a net margin of 7.82%. The firm's quarterly revenue was down 15.8% on a year-over-year basis. During the same period in the prior year, the business posted ($0.35) EPS.
View Ionis Pharmaceuticals' earnings history.

How has Ionis Pharmaceuticals' stock been impacted by COVID-19?

Ionis Pharmaceuticals' stock was trading at $49.14 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IONS stock has decreased by 25.5% and is now trading at $36.61.
View which stocks have been most impacted by COVID-19.

What guidance has Ionis Pharmaceuticals issued on next quarter's earnings?

Ionis Pharmaceuticals updated its FY 2021 earnings guidance on Wednesday, May, 5th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $600 M-, compared to the consensus revenue estimate of $632.68 million.

What price target have analysts set for IONS?

15 brokers have issued 12 month target prices for Ionis Pharmaceuticals' stock. Their forecasts range from $35.00 to $86.00. On average, they anticipate Ionis Pharmaceuticals' share price to reach $57.59 in the next year. This suggests a possible upside of 57.3% from the stock's current price.
View analysts' price targets for Ionis Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Ionis Pharmaceuticals' key executives?

Ionis Pharmaceuticals' management team includes the following people:

Dr. Stanley T. Crooke, Founder & Exec. Chairman (Age 76, Pay $1.97M)
Dr. Brett P. Monia, Founder, CEO & Director (Age 60, Pay $1.06M)
Ms. Elizabeth L. Hougen, Exec. VP of Fin. & CFO (Age 59, Pay $834.19k)
Mr. Patrick R. O'Neil, Exec. VP of Legal, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 47, Pay $816.23k)
Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 67, Pay $1.36M)
Dr. Richard S. Geary, Exec. VP & Chief Devel. Officer (Age 63, Pay $829.79k)
Mr. Darren Gonzales, Chief Accounting Officer & Sr. VP
Dr. C. Frank Bennett, Exec. VP & Chief Scientific Officer (Age 64)
Mr. D. Wade Walke, VP of Investor Relations
Ms. Roslyn Patterson M.B.A., VP of Marketing & Communications

Who are some of Ionis Pharmaceuticals' key competitors?

Some companies that are related to Ionis Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), United Therapeutics (UTHR) and Neurocrine Biosciences (NBIX).
View all of IONS's competitors.

What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.64%), Swiss National Bank (0.36%), Nikko Asset Management Americas Inc. (0.35%), Dowling & Yahnke LLC (0.22%), Baillie Gifford & Co. (0.17%) and BLB&B Advisors LLC (0.11%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke.
View institutional ownership trends for Ionis Pharmaceuticals.

Which institutional investors are selling Ionis Pharmaceuticals stock?

IONS stock was sold by a variety of institutional investors in the last quarter, including Dowling & Yahnke LLC, Victory Capital Management Inc., State of New Jersey Common Pension Fund D, Rhumbline Advisers, Natixis Advisors L.P., Reynders McVeigh Capital Management LLC, Handelsbanken Fonder AB, and NN Investment Partners Holdings N.V.. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen, and Stanley T Crooke.
View insider buying and selling activity for Ionis Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Ionis Pharmaceuticals stock?

IONS stock was acquired by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Baillie Gifford & Co., DnB Asset Management AS, NJ State Employees Deferred Compensation Plan, Envestnet Asset Management Inc., Emerald Advisers LLC, and US Bancorp DE.
View insider buying and selling activity for Ionis Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ionis Pharmaceuticals' stock price today?

One share of IONS stock can currently be purchased for approximately $36.61.

How much money does Ionis Pharmaceuticals make?

Ionis Pharmaceuticals has a market capitalization of $5.16 billion and generates $1.12 billion in revenue each year. The company earns $303.26 million in net income (profit) each year or $2.08 on an earnings per share basis.

How many employees does Ionis Pharmaceuticals have?

Ionis Pharmaceuticals employs 757 workers across the globe.

What is Ionis Pharmaceuticals' official website?

The official website for Ionis Pharmaceuticals is www.ionispharma.com.

Where are Ionis Pharmaceuticals' headquarters?

Ionis Pharmaceuticals is headquartered at 2855 GAZELLE COURT, CARLSBAD CA, 92010.

How can I contact Ionis Pharmaceuticals?

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200 or via email at [email protected]

This page was last updated on 5/7/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Ionis Pharmaceuticals Stock Forecast, Price & News

Adding

Adding

Adding Ionis Pharmaceuticals, Inc.

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Headlines

About Ionis Pharmaceuticals

MarketRank™

Overall MarketRank™